دورية أكاديمية
أعرض في EDS

Environmentally benign first derivative synchronous spectrofluorimetry for the analysis of two binary mixtures containing duloxetine with avanafil or tadalafil in spiked plasma samples.

التفاصيل البيبلوغرافية
العنوان: Environmentally benign first derivative synchronous spectrofluorimetry for the analysis of two binary mixtures containing duloxetine with avanafil or tadalafil in spiked plasma samples.
المؤلفون: Abd-AlGhafar WN; Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt., Abo Shabana R; Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt., El-Shaheny R; Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt., Tolba MM; Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
المصدر: Luminescence : the journal of biological and chemical luminescence [Luminescence] 2024 Mar; Vol. 39 (3), pp. e4696.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley & Sons Country of Publication: England NLM ID: 100889025 Publication Model: Print Cited Medium: Internet ISSN: 1522-7243 (Electronic) Linking ISSN: 15227235 NLM ISO Abbreviation: Luminescence Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Chichester, Sussex, UK : Wiley & Sons, c1999-
مواضيع طبية MeSH: Pyrimidines*, Humans ; Tadalafil ; Duloxetine Hydrochloride ; Pharmaceutical Preparations ; Spectrometry, Fluorescence/methods
مستخلص: Antidepressants can cause sexual dysfunction side effects, necessitating the co-administration of phosphodiesterase type 5 inhibitors. The simultaneous determination of these drugs in biological fluids is critical for therapeutic drug monitoring. For the first time, two binary mixtures containing duloxetine with either avanafil or tadalafil were estimated utilizing simple green spectrofluorimetric methods without the need for a previous separation step. The study was based on first derivative synchronous spectrofluorimetry in ethanol using a change in wavelength difference (∆λ) of 20 and 25 nm for the first and second combinations, respectively. Duloxetine and avanafil were estimated at 297.7 and 331 nm in their binary mixture, while duloxetine and tadalafil were determined at 290.3 and 297.7 nm, respectively. The linearity was achieved over the ranges of 0.1-1.5 μg mL -1 for both duloxetine and avanafil and 0.01-0.40 μg mL -1 for tadalafil, with limits of detection of 0.013, 0.022, and 0.004 μg mL -1 for duloxetine, avanafil, and tadalafil, respectively. Successful application of the developed approaches was accomplished for the estimation of the two mixtures in dosage forms as well as human plasma with excellent percentage recoveries (96-103.75% in plasma), which supports their suitability for use in quality control laboratories and pharmacokinetic studies. Moreover, the adopted approaches' greenness was evidenced by applying three tools.
(© 2024 John Wiley & Sons Ltd.)
References: L. L. Brunton, B. C. Knollmann, Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed., The McGraw‐Hill Companies, New York 2022.
Depression affects about 280 million people worldwide. https://www.washingtonpost.com/health/2022/02/27/depression-worldwide/ (Accessed May 3, 2023).
M. Fava, J. Clin. Psychiatry 2006, 67, 14.
S. H. Kennedy, S. Rizvi, J. Clin. Psychopharmacol. 2009, 29, 157.
M. Gabriel, V. Sharma, Can. Med. Assoc. J. 2017, 189, E747.
The British Pharmacopoeia, British Pharmacopoeia Commission, Electronic version, Stationary Office, London, 2022.
M. P. Freeman, A. M. Hirschberg, B. Wang, L. F. Petrillo, S. Connors, S. Regan, H. Joffe, L. S. Cohen, Maturitas 2013, 75, 170.
A. Sultan, H. Gaskell, S. Derry, R. A. Moore, BMC Neurol. 2008, 8, 1.
R. Bennett, I. J. Russell, E. Choy, M. Spaeth, P. Mease, D. Kajdasz, D. Walker, F. Wang, A. Chappell, Clin. Ther. 2012, 34, 824.
B. Mihaylova, R. Pitman, D. Tincello, H. Vaart, R. Tunn, L. Timlin, D. Quail, A. Johns, M. Sculpher, Value Health 2010, 13, 565.
A. Kamal, G. R. Khanna, R. Ramu, T. Krishnaji, Tetrahedron Lett. 2003, 44, 4783.
Lowtcenter, Reinventing men's health. https://lowtcenter.com/news-article/antidepressants-cause-erectile-dysfunction/ (Accessed May 15, 2023).
M. J. Taylor, L. Rudkin, P. Bullemor‐Day, J. Lubin, C. Chukwujekwu, K. Hawton, Cochrane Database Syst. Rev. 2013, 5, CD003382.
S. Tatar Ulu, J. Chromatogr. Sci. 2012, 50, 494.
J. W. Chae, H. M. Baek, S. K. Kim, H. I. Kang, K. I. Kwon, Biomed. Chromatogr. 2013, 27, 953.
X. Chen, C. Liang, L. Cui, J. Le, Z. Qian, R. Zhang, Z. Hong, Y. Chai, J. Food Drug Anal. 2019, 27, 323.
F. Micheal, B. Musuvathi, M. Sayana, R. P. Muppavarapu, Res. J. Pharm. Technol. 2020, 13, 2117.
R. V. Amirtha, T. Ramesh, A. P. Kumar, Int. J. Pharma. Bio. Sci. 2011, 2, 717.
R. Chadha, A. Bali, Br. J. Pharm. Res. 2015, 6, 402.
L. Samal, A. Prusty, Int. J. Pharm. Pharm. Sci. 2019, 11, 27.
S. L. Prabu, S. Shahnawaz, C. D. Kumar, A. Shirwaikar, Indian J. Pharm. Sci. 2008, 70, 502.
W. Misiuk, Indian J. Chem. A 2012, 51, 1706.
N. A. Alarfaj, R. A. Ammar, M. F. El‐Tohamy, Asian J. Chem. 2013, 25, 6416.
O. Sagirli, S. E. Toker, A. Önal, Luminescence 2014, 29, 1014.
S. M. Derayea, R. Ali, A. A. Abu‐Hassan, R. Soc. Open Sci 2021, 8, 210922.
M. Limin, N. Johnson, W. J. Hellstrom, Expert Opin. Invest. Drugs 2010, 19, 1427.
L. H. Belkoff, A. McCullough, I. Goldstein, L. Jones, C. H. Bowden, K. DiDonato, B. Trashand, W. W. Day, Int. J. Clin. Pract. 2013, 4, 333.
R. Kashyap, U. Srinivasa, K. Badodaria, W. J. Pharm. Pharm. Sci. 2014, 3, 1697.
M. Hegazy, A. Kessiba, M. Abdelkawy, A. E. El‐Gindy, J. Liq. Chrom. Rel. Tech. 2015, 38, 1660.
B. Bhumik, R. Kashyap, S. Buddhadev, Int. J. Pharm Drug Anal. 2015, 3, 181.
J. H. Lee, J. H. Jeong, H. Park, J. Do, S. Heo, S. Cho, C. Yoon, Anal. Sci. Technol. 2016, 29, 155.
U. A. Fahmy, B. M. Aljaeid, Int. J. Adv. Pharm. Biol. Chem. 2016, 5, 59.
D. A. Shah, K. L. Vegad, E. D. Patel, H. K. Prajapati, R. N. Patel, Y. K. Patel, Pharm. Biol. Eval. 2017, 4, 171.
N. Kumar, D. Sangeetha, L. Kalyanraman, K. Sainath, Acta Chromatogr. 2017, 30, 158.
E. Ö. Er, B. Özbek, S. Bakırdere, Measur. 2018, 124, 64.
E. Öztürk Er, B. Özbek, S. Bakırdere, J. Sep. Sci. 2019, 42, 475.
E. Ö. Er, E. Akkaya, B. Özbek, S. Bakırdere, Microchem. J. 2020, 152, 104302.
M. N. Patel, C. S. Kothari, J. AOAC Int. 2016, 99, 649.
M. K. Darwish, M. M. Soliman, S. A. Abdel‐Razeq, Asian J. Chem. Sci. 2019, 6, 1.
P. M. Tailor, V. V. Patel, A. D. Mishra, S. A. Shah, D. R. Shah, Res. Rev. J. Drug Formul. Dev. Prod. 2016, 3, 1.
T. A. Mohamed, S. A. Atty, Spectrochim. Acta a 2020, 229, 117898.
A. M. Abdel‐Raoof, R. A. M. Said, M. S. Emara, E. A. El‐Desouky, A. M. Abdelzaher, M. A. Hasan, A. E. Osman, Spectrochim. Acta a 2020, 235, 118313.
R. M. Coward, C. C. Carson, Ther. Clin. Risk Manag. 2008, 4, 1315.
C. A. Farthing, D. E. Farthing, S. Koka, T. Larus, I. Fakhry, L. Xi, T. W. Gehr, J. Chromatogr., B 2010, 878, 2891.
M. H. Mehanna, A. M. Motawaa, M. W. Samaha, J. AOAC Int. 2012, 95, 1064.
M. Hamad, A. Al‐Sharqawi, W. A. Dayyih, E. Mallah, T. Arafat, J. Appl. Pharm. Sci. 2016, 6, 52.
M. Yunoos, D. G. Sankar, B. P. Kumar, S. Hameed, E‐J. Chem. 2010, 7, 833.
R. El Shiekh, A. S. Amin, E. M. Hafez, A. A. Gouda, Pharm. Lett. 2016, 8, 153.
M. R. Rezk, M. A. Tantawy, M. Wadie, S. A. Weshahy, Spectrochim. Acta a 2020, 227, 117547.
M. A. Magdy, B. H. Anwar, I. A. Naguiband, N. S. Abdelhamid, Spectrochim. Acta a 2020, 226, 117611.
M. A. Abu El‐Enin, M. E. A. Hammouda, D. T. El‐Sherbiny, D. R. El‐Wasseef, S. M. El‐Ashry, Luminescence 2016, 31, 173.
A. Eiroa, G. De‐Armas, J. Estela, V. Cerda, TrAC, Trends Anal. Chem. 2010, 29, 885.
C. Capello, U. Fischer, K. Hungerbühler, Green Chem. 2007, 9, 927.
J. Płotka‐Wasylka, Talanta 2018, 181, 204.
A. Gałuszka, P. Konieczka, Z. M. Migaszewski, J. Namiesnik, TrAC, Trends Anal. Chem. 2012, 37, 61.
F. Pena‐Pereira, W. Wojnowski, M. Tobiszewski, Anal. Chem. 2020, 92, 10076.
M. Sajid, J. Płotka‐Wasylka, Talanta 2022, 238, 123046.
M. H. El‐Maghrabey, V. Sivasankar, R. N. El‐Shaheny, Green Chemical Analysis and Sample Preparations, 1st ed., London, UK, Springer Nature 2022.
M. Gamal, I. A. Naguib, D. S. Panda, F. F. Abdallah, Anal. Methods 2021, 13, 369.
K. M. Billiard, A. R. Dershem, E. Gionfriddo, Molecules 2020, 25, 5297.
R. Ahmed, I. Abdallah, Molecules 2020, 25, 4932.
S. S. Ferreira, T. A. Brito, A. P. Santana, T. G. Guimarães, R. S. Lamarca, K. C. Ferreira, P. C. F. Lima Gomes, A. Oliveira, C. D. B. Amaral, M. H. Gonzalez, Talanta Open 2022, 6, 100131.
M. A. Abdel‐Lateef, M. A. Omar, R. Ali, S. M. Derayea, Spectrochim. Acta a 2019, 206, 57.
European Medicines Agency, Science Medicines Health, Committee for Medicinal Products for Human Use (CHMP) assessment report. https://www.ema.europa.eu/en/documents/assessment-report/spedra-epar-public-assessment-report_en.pdf (Acessed December 15, 2023).
X. Liu, Y. Du, X. Wu, Spectrochim. Acta, Part a 2008, 71, 915.
A. Nahata, Pharm. Anal. Acta. 2011, 2, 8.
J. Isac‐García, J. A. Dobado, F. G. Calvo‐Flores, H. Martínez‐García, Experimental Organic Chemistry: Laboratory Manual, 1st ed., Academic Press, Amsterdam, The Netherlands 2016.
International Council for Harmonization of technical requirements for pharmaceuticals for human use, ICH harmonized guideline Q2(R1), validation of analytical procedures, 2022.
J. N. Miller, J. C. Miller, Statistics and Chemometrics for Analytical Chemistry, 7th ed., Pearson Education Limited, Harlow, England 2018.
A. K. Kammoun, A. Khedr, O. A. Ahmed, RSC Adv. 2020, 10, 9407.
J. E. Frampton, G. L. Plosker, CNS Drugs 2007, 21, 581.
R. Al‐Shalabi, M. Hefnawy, H. Alrabiah, H. Al‐Johar, M. Mohammed, M. Alanazi, A. Almehizia, M. Abounassif, Y. B. Jardan, Curr. Pharm. Anal. 2019, 15, 399.
J. W. Chae, H. M. Baek, S. K. Kim, H. I. Kang, K. I. Kwo, Biomed. Chromatogr. 2013, 27, 953.
E. G. Katz, R. B. Tan, D. Rittenberg, W. J. Hellstrom, Ther. Clin. Risk Manag. 2014, 10, 701.
S. T. Forgue, B. E. Patterson, A. W. Bedding, C. D. Payne, D. L. Phillips, R. E. Wrishko, M. I. Mitchell, Br. J. Clin. Pharmacol. 2006, 61, 280.
L. H. Keith, L. U. Gron, J. L. Young, Chem. Rev. 2007, 107, 2695.
فهرسة مساهمة: Keywords: avanafil; derivative synchronous spectrofluorimetry; duloxetine; human plasma; tadalafil
المشرفين على المادة: 742SXX0ICT (Tadalafil)
9044SC542W (Duloxetine Hydrochloride)
DR5S136IVO (avanafil)
0 (Pyrimidines)
0 (Pharmaceutical Preparations)
تواريخ الأحداث: Date Created: 20240317 Date Completed: 20240319 Latest Revision: 20240321
رمز التحديث: 20240321
DOI: 10.1002/bio.4696
PMID: 38494193
قاعدة البيانات: MEDLINE
الوصف
تدمد:1522-7243
DOI:10.1002/bio.4696